US Patent

US9127013 — Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds

Composition of Matter · Assigned to Array Biopharma Inc · Expires 2029-10-21 · 3y remaining

Vulnerability score 0/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects the method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds, such as larotrectinib sulfate, for various conditions in mammals.

USPTO Abstract

Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.

Drugs covered by this patent

larotrectinib-sulfate (LAROTRECTINIB SULFATE)

Patent Metadata

Patent number: US9127013
Jurisdiction: US
Classification: Composition of Matter
Expires: 2029-10-21
Drug substance claim: Yes
Drug product claim: Yes
Assignee: Array Biopharma Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.